NDAORALSUSPENSION
Approved
Aug 1981
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
3/8 — Basic
ALDOMET (methyldopa) by Merck & Co. is clinical pharmacology methyldopa is an aromatic-aminoacid decarboxylase inhibitor in animals and in man. First approved in 1981.
Drug data last refreshed 13h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ALDOMET (methyldopa) is an oral antihypertensive agent approved in 1981 that works by inhibiting aromatic-aminoacid decarboxylase and metabolizing to alpha-methylnorepinephrine, which stimulates central inhibitory alpha-adrenergic receptors to lower blood pressure. It is used primarily for hypertension management and is notable for maintaining cardiac output without acceleration while producing smooth, sustained blood pressure reduction.
LOE Approaching
Product is approaching loss of exclusivity with moderate competitive pressure (30/100), indicating shrinking brand team and transition focus toward cost management and market defense.
Mechanism of Action
CLINICAL PHARMACOLOGY Methyldopa is an aromatic-aminoacid decarboxylase inhibitor in animals and in man. Although the mechanism of action has yet to be conclusively demonstrated, the antihypertensive effect of methyldopa probably is due to its metabolism to alpha-methylnorepinephrine, which then…
Worked on ALDOMET at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.